Company Overview of Hutchison MediPharma Limited
Hutchison MediPharma Limited, a drug research and development company, engages in the discovery, development, and commercialization of therapeutics for oncology and autoimmune diseases in North America, Europe, Australia, and Greater China. Its portfolio includes HMPL-004, an oral botanical product that acts on multiple targets in the pathogenesis of inflammatory bowel disease; Sulfatinib/HMPL-012, a small molecule that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor (VEGF) and fibroblast growth factor receptors; and Fruquintinib/HMPL-013, a small molecule compound that selectively inhibits VEGF receptors; Epitinib/HMPL-813, an orally acti...
917 Halei Road
Zhangjiang Hi-Tech Park
Founded in 2002
Key Executives for Hutchison MediPharma Limited
Interim Chief Executive Officer and Director
Chief Scientific Officer and Executive Vice President of Drug Research
Head of Drug Metabolism & Pharmacokinetics and Vice President
Senior Vice President of Pharmaceutical Sciences
Senior Vice President and Head of Clinical Development & Regulatory Affairs
Compensation as of Fiscal Year 2014.
Hutchison MediPharma Limited Key Developments
Hutchison MediPharma Limited Announces Initiation of Fruquintinib Phase III Registration Study in Colorectal Cancer
Dec 15 14
Hutchison MediPharma Limited (HMP), has initiated FRESCO, a Phase III registration study in colorectal cancer (CRC) patients in China, for fruquintinib (HMPL-013), its investigational small molecule which selectively inhibits vascular endothelial growth factor receptors (VEGFR). Preparations and site selection began in the middle of this year, with the first patient dosed on 12 December 2014. This randomised, double-blind, placebo-controlled, multicentre, Phase III registration study is targeted at treating patients with locally advanced or metastatic CRC, who have failed at least two prior systemic antineoplastic therapies, including fluoropyrimidine, oxaliplatin and irinotecan. Patients will be randomised at a 2:1 ratio to receive either: 5 milligrams of fruquintinib orally once per day, on a three-weeks-on /one-week-off cycle, plus best supportive care (BSC); or placebo plus BSC. The primary endpoint is overall survival, with secondary endpoints including progression free survival, objective response rate, disease control rate and duration of response. More than 400 patients will be enrolled in about 25 centres, with top-line results expected in 2016. Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. At an advanced stage, tumours secrete large amounts of VEGF, a protein ligand, to stimulate formation of excessive vasculature (angiogenesis) around the tumour in order to provide greater blood flow, oxygen, and nutrients to the tumour. VEGF and VEGF receptors (VEGFRs) play a pivotal role in tumour -related angiogenesis, and inhibition of the VEGF/VEGFR pathway. This represents therapeutic strategy in blocking the development of new blood vessels essential for tumours to grow and invade. To date, several anti-VEGF/VEGFR agents have shown clinical efficacy against a number of tumour types. Given the scale and growth in the China oncology market, the market for VEGF/VEGFR inhibitors in China is expected to develop quickly in the next few years.
Hutchison Medipharma Limited Completes Patient Enrolment in Phase II Clinical Trial of Fruquintinib in Colorectal Cancer in China
Aug 21 14
Hutchison MediPharma Limited has completed patient enrolment in a Phase II clinical trial of fruquintinib in colorectal cancer in China. The proof-of-concept study is investigating the efficacy and safety of fruquintinib, HMP's investigational small molecule inhibitor of vascular endothelial growth factor receptors. This randomised, double-blind, placebo-controlled, multi-centre, proof-of-concept Phase II study is targeted at treating patients with metastatic CRC, who have failed at least two prior chemotherapies, including fluoropyrimidine, oxaliplatin and irinotecan. A total of 71 patients have now been randomised to receive fruquintinib plus best supportive care or placebo plus BSC at a 2:1 ratio. The primary endpoint is progression free survival, with secondary endpoints including disease control rate, overall response rate, overall survival and safety. As a result of the rapid patient enrolment, data from this trial is expected in early 2015. Fruquintinib is designed to selectively inhibit VEGF receptors, namely VEGFR1, VEGFR2, and VEGFR3. In the first-in-human Phase I clinical trial 40 patients were treated with fruquintinib.
Hutchison MediPharma Limited Starts Phase I Clinical Trial with HMPL-523
Jun 18 14
Hutchison China MediTech Limited announced that Hutchison MediPharma Limited has initiated the first-in-human Phase I clinical trial of HMPL-523 in Australia. HMPL-523 is a novel, highly selective and potent small molecule inhibitor targeting spleen tyrosine kinase, also known as Syk, a key component in B-cell receptor signalling. HMPL-523 is HMP's second active immunology programme in clinical development. The first drug dose was administered on 17 June 2014. As one of the major cellular components of the immune system, B-cells play pivotal roles in autoimmune diseases. Targeted B-cell receptor signalling therapy has been proven to be clinically effective for the treatment of rheumatoid arthritis ("RA") and B-cell malignancies, leading to scientific and commercial success. Syk is an essential enzyme involved in B-cell receptor signalling pathway and a novel target for investigational therapies in immunology and oncology. HMPL-523 is being developed as an oral formulation for the treatment of autoimmune diseases such as RA and lupus. In preclinical studies, HMPL-523 demonstrated superior potency and kinase selectivity, a reversal of the progression of joint inflammation and bone erosion along with a reduced production of multiple pro-inflammatory cytokines, as well as a favourable safety margin in both rodent and non-rodent toxicology studies. The first-in-human trial aims to establish the safety profile of HMPL-523. This randomised, double blind, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses of HMPL-523 will be conducted in healthy volunteers. Initial results are expected around the end of 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|